Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

NCT04718870 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis Atopic

Interventions

DRUG: Dupilumab SAR231893

Sponsor

Sanofi

Collaborators

[object Object]